 |
4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one |
|---|---|
| Trade Name | |
| Orphan Indication | Congenital long QT syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2015-05-04 00:00:00 |
| Sponsor | Gilead Sciences, Inc.;333 Lakeside Drive;Foster City, California, 94404 |
